Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Promising pregnancy drug study pulled before it began

NCT ID NCT04275778

First seen Apr 17, 2026 · Last updated Jun 17, 2026 · Updated 9 times

Summary

This study aimed to see if adding hydroxychloroquine to standard treatment (aspirin and blood thinners) could help more women with antiphospholipid syndrome have healthy, full-term pregnancies. The trial planned to enroll pregnant women before 14 weeks, but it was withdrawn and no one participated. The condition increases risks of miscarriage and complications, and hydroxychloroquine was hoped to reduce those risks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTICOAGULANTS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Hopital Saint Antoine

    Paris, 75012, France

Conditions

The condition(s) this trial relates to.

antiphospholipid syndrome primary antiphospholipid syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.